← All trials
NCT02592486
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2015
- Primary completion
- Mar 1, 2016
- Completion date
- Aug 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 162
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Kameda Medical CenterLead sponsor
- MerckCollaborator
- Kameda Medical CenterReponsible party - principal investigator
- Kameda Medical CenterOverall official - principal investigator
- PPDCollaborator
- Osaka UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.